菲沃泰：聘任赵钱波为公司董事会秘书、财务总监

Group 1 - The company announced the resignation of Mr. Zong Jian and Mr. Sun Xilin from their positions as Chief Financial Officer and Secretary of the Board, respectively, due to work adjustments [1] - To enhance internal operational management efficiency, the company appointed Ms. Zhao Qianbo as the new Secretary of the Board and Chief Financial Officer after a thorough review process [1] - For the fiscal year 2024, the company's revenue composition is projected to be 93.95% from manufacturing and 6.05% from other businesses [1] Group 2 - The company's market capitalization is currently valued at 8 billion yuan [2] - The Chinese innovative drug sector has generated 80 billion USD in overseas licensing deals this year, indicating a robust secondary market for biopharmaceuticals [2]